Chloe Slichter
Director – Discovery Biology Kite Pharma
Chloe Slichter, Ph.D., is a Director at Kite Pharma where she leads efforts to advance CAR T cell therapies for oncology and autoimmune disease. Chloe focuses on understanding CAR T cell biology and using novel engineering approaches to improve therapeutic efficacy. Her work integrates cutting edge cellular engineering and translational research to drive innovation in adoptive cell therapy.
Seminars
- Matching the modality to the pathogenic cell subset driving the disease
- Comparing the logistical and risk profiles of different classes of therapies and defining an acceptable risk-benefit ratio for large autoimmune patient populations
- Exploring the potential for combination therapies pairing a single dose reset agent with a subsequent maintenance modality to enhance durability and reduce relapse risk
Join this session to hear the thoughts of experts who have successfully moved precision therapies from the oncology world into autoimmune diseases:
- Discussing whether the therapeutic goal should be complete depletion of peripheral B-cells or elimination of tissue resident B-cells that drive local pathology
- Addressing the risks associated at various level of depletion such as elevated BAFF
- Debating whether targeted depletion of specific pathogenic subsets is superior to non-selective deep depletion
Join this session for a candid conversation with experts pursuing the reality of of-the-shelf cell therapies:
- Discussing the advantages of using allogeneic approaches over autologous approaches to make immune resetting scalable for large autoimmune patient populations
- Focusing on necessary gene-editing strategies and conditioning regimens to eliminate the risk of graft vs host disease and other safety concerns
- Deep diving into current indications being explored for allogeneic cell therapy
Defining Immune Resetting: Translational Approaches to Profiling B-Cells to Understand the Depth of Depletion
Join this workshop to discuss how we measure the immune reset and to what depth must we deplete B-Cells:
- Clarifying the constitution of a true ‘immune reset’ following B-cell depletion therapy vs transient immunosuppression
- Discussing the restoration of the stable self-tolerant immune system
- Understanding optimal depletion targets to understand which populations must be depleted and to what extent to achieve a sustainable therapeutic effect
- Reflecting on the necessary therapeutic strategies needed to target long-lived plasma cells within the bone marrow
- Advancing B-cell profiling techniques such as single-cell RNA sequencing, flow, and mass cytometry, and adaptive immune receptor repertoire sequencing
- Discussing the effective definition of B-cell depletion through cellular and molecular biomarkers that correlate with depletion depth and sustained immune reset
- Distinguishing diseases driven by CD20+ B-Cells from those driven by plasma cells to inform the choice of alternative targets such as BCMA and CD38
- Harnessing base editing to enable CAR T-cell combination therapies for B-cell targeting and beyond
- Discussing the possibility of B-cell reconstitution, focusing on whether the new B-cell compartment is “reset” to a non-autoreactive state
